-- Seasoned finance executive has raised $1B+ in equity financing to scale
     biofacturing platform for commercial markets

Biofacturing leader Zymergen ( 
https://c212.net/c/link/?t=0&l=en&o=3077202-1&h=1965526795&u=http%3A%2F%2Fwww.zymergen.com%2F&a=Zymergen 
) today announced it has promoted Enakshi (Ena) Singh to Chief Financial 
Officer. Singh has helped Zymergen close more than $1B in equity financing and 
$100M in debt since joining Zymergen as vice president of finance in 2014, 
fueling the company's early growth, testing, de-risking, and product 
development. Singh's promotion comes as Zymergen moves into commercial and 
operational scaling, following the $300M in new investment ( 
https://c212.net/c/link/?t=0&l=en&o=3077202-1&h=2047817159&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fzymergen-takes-aim-at-3-trillion-chemical--materials-industry-with-300-million-in-new-funding-301125840.html&a=%24300M+in+new+investment 
) last year, which has further accelerated their discovery and production of 
novel, high-performance materials.

Photo - https://mma.prnewswire.com/media/1443697/Zymergen_CFO_Ena_Singh.jpg 
Logo - https://mma.prnewswire.com/media/1218528/Zymergen_Logo.jpg 

"Ena has a proven track record earning the confidence of some of the leading 
and most demanding global investors to embrace the power and opportunity of 
biofacturing," says Josh Hoffmann, Zymergen CEO. "Our business is not your 
typical cloud or biotech platform, and Ena has charted a masterful financial 
course for a new kind of science and technology company. She is the right 
person to lead financial strategy for our next chapter, focusing on expanding 
our commercial operations and sales."

Singh previously served as SVP of asset management at Mubadala, Abu Dhabi's 
$230B sovereign wealth fund, where she led complex semiconductor investments 
involving specialized manufacturing and unique investment and scaling models 
that are a direct parallel for Zymergen's biofacturing platform. Previously, 
she was the VP of technology investment banking at Merrill Lynch and an analyst 
for Latin American investment banking at Salomon Smith Barney. She earned a BA 
in economics at Cornell University and an MBA at MIT Sloan School of Management.

"Ena's ability to seamlessly move between investors and customers, coupled with 
her deep understanding of Zymergen's business model and technology platform, 
has garnered enthusiastic support from the board and investors alike," said 
Sandi Peterson, Zymergen board member and former Group Worldwide Chairwoman of 
Johnson & Johnson. "She brings the right experience at the right time to lead 
Zymergen's expansion into commercial markets."

"In seven years, Zymergen has grown from an idea to a thriving platform 
company, with one product in market and many more on the way," said Singh. 
"Zymergen is winning customer confidence that we can discover breakthrough 
materials, and also scale and deliver them to demanding markets like 
electronics, consumer care and agriculture. Innovators seek new materials to 
accomplish today's toughest challenges - and Zymergen's biofacturing platform 
is delivering."

Based on our early experience, Zymergen develops and launches high-performance 
products more sustainably and for a fraction of the cost and time that it 
typically takes using legacy petrochemical techniques. A unique combination of 
biology, chemistry, software and automation fuels Zymergen's high-throughput 
biodiscovery engine, enabling the company to discover, design and commercialize 
new materials at unprecedented speed. 

About Zymergen 
Zymergen is a biofacturing company using biology to reimagine the world. 
Zymergen partners with nature to create, develop and manufacture breakthrough 
products and materials across industries - from agriculture to electronics, 
consumer care to pharmaceuticals, and more. The company produces a suite of 
high performing, sustainable materials in use today, delivering value for 
Fortune 500 companies with over $1 billion worth of products using Zymergen 
microbial innovations sold to date. Learn more at http://zymergen.com.

SOURCE: Zymergen

CONTACT:  zymergen@methodcommunications.com